With the ever-increasing complexity of clinical development and market dynamics, more pharma companies are under-achieving against commercialization timelines and commercial expectations, leaving significant value on the table. One major contributor to underperformance is companies’ restricted ability to react in a timely manner to change. Too often, companies have little in the way of alternatives to Plan A for their pipeline assets. Despite having identified different scenarios and associated forecasts, current models of contingency planning are typically insufficient to enable companies to switch gear easily when needed.

To minimize delays and maximize revenue potential, companies need to allocate time and dedicated budgets to mapping out alternative development routes and implementing well-structured contingency plans, affording them vital agility. To scope the challenge facing PharmaCos, we conducted a deeper quantitative analysis of launch activity over the past 15 years and have developed a new and more structured approach to developing differentiated assets within the anticipated timelines, on a consistent basis.

Register now to find out how Contingency Planning 2.0 helps you to de-risk development and optimize choices beyond clinical development.